Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) obtained China's regulatory approval for first phase clinical trials of subcutaneous injection HLX15-SC for multiple myeloma treatment.
HLX15 is a daratumumab biosimilar independently developed by the company, according to a Thursday filing with the Shanghai bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.